1.Blood pressure, hypertension and other cardiovascular risk factor in six communities in Papua New Guinea, 1985-1986
H. King ; V. Collins ; L. F. King ; C. Finch ; M. P. Alpers
Papua New Guinea medical journal 1994;37(2):100-109
Surveys of noncommunicable diseases were performed in six communities in Papua New Guinea during 1985-1986. Results are reported here with respect to blood pressure and associated factors in adults. Mean systolic and diastolic blood pressures were lowest, and hypertension was rarest (less than 2%), in three rural/semirural villages on Karkar Island, Madang Province. Intermediate values for blood pressure and moderate prevalence of hypertension (3-6%) were observed in rural and urban Tolai communities in East New Britain Province. A periurban village in the Eastern Highlands Province displayed the highest mean blood pressures and prevalence of hypertension (12% in men and 5% in women). There was a modest rise in mean systolic blood pressure with age in most groups, but the age-related rise in diastolic pressure was much less pronounced. Other cardiovascular risk factors--body mass index (BMI), and plasma cholesterol, glucose and insulin concentrations--were lowest in the least developed rural villages on Karkar Island and highest in the urban Tolai and periurban highland communities. Both systolic and diastolic blood pressures were significantly (and positively) related to age, male sex, BMI and speaking a non-Austronesian language. It is concluded that there is now a considerable variation in the prevalence of hypertension, and the levels of blood pressure and other cardiovascular risk factors, in different communities in Papua New Guinea.
Adult
;
Blood Pressure
;
Cardiovascular Diseases - etiology
;
Diabetes Mellitus - epidemiology
;
Hypertension - complications
;
Obesity - epidemiology
;
Papua New Guinea
2.Clinical study on cholesterol-lowering effect of RYR Cholestin among Americans with moderate hy-percholesterolemia
Ji-Hong LU ; Bonovich KERMIT ; Colfer HARRY ; Davidson MICHAEL ; A.Dujo-Vne CARLOS ; Fried L. DAVID ; Greenspan MITCHELL ; Karlsberg P. RONALD ; King P. STEPHEN ; LaForce F. CRAIG ; Litt MARC ; McGhee J.ROBERT ; Run-Hai ZENG ; Jia-Shi ZHU ; Ning-Zhi TAN
Shanghai Journal of Preventive Medicine 2013;(9):501-506
[Objective] To evaluate lipid -lowering efficacy and safety of RYR Cholestin , or Monascus purpureus (Red Yeast) Rice, in Americans with moderate hypercholesterolemia. [Methods] This study was an open-label, self-control, and multi-center clinical trial.A total of 187 subjects were entered into this trial (serum LDL-Cholesterol 3.50~4.92 mmol/L,total cholesterol 5.18~7.25 mmol/L, male:female=116∶71) , of whom 162 completed the study .Subjects were placed on the NCEP Step I Diet throughout the study and RYR Cholestin (2.4 g/day) was administered for 8 weeks following initial 4-week diet control . [ Results] Being on the diet alone for 4 weeks resulted in no significant changes in serum lipids .RYR Cholestin treatment for 8 weeks reduced serum total cholesterol , LDL-Cholesterol and triglycerides by 16 .6%, 24 .0%, and 25 .2%, respectively , and increased HDL-Cholesterol by 14 .3%( all P<0 .001 ) .There were 97 .5% of patients having ≥10% improvement in at least one of lipid risk factors, and 79.0%having ≥20% improvement.Discontinuation of RYR Cholestin intervention for 14 d led to a return of serum lipids to baseline of pre -study .And 29 possible product -related mild adverse re-actions were reported . [ Conclusion] RYR Cholestin is well tolerated and effective in reducing total and LDL-Cholesterol, and triglycerides, as well as in increasing HDL-Cholesterol in hypercholesterolemic patients, but those indicators return to the beginning baseline when the treatment is discontinued .
3.2021 Asian Pacific Society of Cardiology Consensus Recommendations on the use of P2Y12 receptor antagonists in the Asia-Pacific Region: Special populations.
W E I C H I E H T A N TAN ; P C H E W CHEW ; L A M T S U I TSUI ; T A N TAN ; D U P L Y A K O V DUPLYAKOV ; H A M M O U D E H HAMMOUDEH ; Bo ZHANG ; Yi LI ; Kai XU ; J O N G ONG ; Doni FIRMAN ; G A M R A GAMRA ; A L M A H M E E D ALMAHMEED ; D A L A L DALAL ; T A N TAN ; S T E G STEG ; N N G U Y E N NGUYEN ; A K O AKO ; A L S U W A I D I SUWAIDI ; C H A N CHAN ; S O B H Y SOBHY ; S H E H A B SHEHAB ; B U D D H A R I BUDDHARI ; Zu Lv WANG ; Y E A N Y I P F O N G FONG ; K A R A D A G KARADAG ; K I M KIM ; B A B E R BABER ; T A N G C H I N CHIN ; Ya Ling HAN
Chinese Journal of Cardiology 2023;51(1):19-31